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Abstract
Background: To explore adolescent HIV risk perception, HIV vaccine knowledge, willingness to
participate in future HIV vaccine clinical trials, and the factors that influence willingness to
participate among high school students in Soweto, South Africa, we recruited school-going youth
through randomly selected local high schools. All pupils within the selected schools from whom
parental consent and child assent could be obtained were eligible for participation. A self-
administered, facilitated questionnaire was completed by all participants.
Findings: Perception of adolescent HIV risk was high. Some misconceptions regarding vaccine
research were common, particularly regarding placebo and potential eligibility criteria for
prophylactic vaccine trials. Of 240 responses to the willingness item, 84 (35%) indicated they were
"probably willing" and 126 (52.5%) that they were "definitely willing to participate". There were no
significant differences in willingness by gender, age, school grade, or institution. Factors that were
rated as "very important" in determining willingness included receiving current information about
HIV research [n = 201 (88.9%)], doing something to honour people who have HIV or have died of
AIDS [n = 168 (70.9%)], getting free counselling and testing [n = 167 (70.5)], that participants may
receive some protection against HIV infection from the vaccine [n = 160 (70.2%)], and improving
motivation to avoid risky behaviour [n = 134 (59%)].
Conclusion: Soweto school-going youth report high degrees of willingness to participate in HIV
vaccine trials. This may be related to the high levels of adolescent HIV risk perception. Whether
hypothetical willingness translates to participation will await data from adolescent HIV vaccine
trials.
Background
In South Africa, adolescents are extremely vulnerable to
HIV infection. Worldwide, about half of all new HIV
infections among adults occur in people under the age of
25 [1]. Each day, 7000 people between the ages of 15 and
24 are infected with HIV worldwide, resulting in 2.6 mil-
lion new infections per year, 1.7 million of which occur in
Africa [2]. Similarly, the highest rates of HIV infection in
South Africa occur among young people [3]. A national
household survey conducted in 2002 estimated that
Published: 29 August 2008
BMC Research Notes 2008, 1:76 doi:10.1186/1756-0500-1-76
Received: 4 April 2008
Accepted: 29 August 2008
This article is available from: http://www.biomedcentral.com/1756-0500/1/76
© 2008 de Bruyn et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Research Notes 2008, 1:76 http://www.biomedcentral.com/1756-0500/1/76
Page 2 of 5
(page number not for citation purposes)
about 10% of 15–24 year old South Africans are living
with HIV [4]. The prevalence rate was 4.8% among boys
and 15.5% among girls of the same age group in a second
national survey conducted in 2004 [5]. While South Afri-
can adolescents have widespread exposure to HIV preven-
tion messages and knowledge of HIV aetiology [6],
perception of vulnerability to HIV remains low [7,8].
High levels of risky sexual behaviour among teens are
exemplified by, for instance, a high teenage pregnancy
rate. The 2004 survey estimated a pregnancy rate of 15.5%
among 15–19 year old South African girls [5]. In light of
these behaviour challenges, an HIV vaccine will be an
important tool for protecting adolescents and therefore
testing promising candidate vaccines amongst adolescents
is required.
Over the last two decades, candidate HIV vaccines have
been studied in safety and efficacy trials involving healthy
adult volunteers, and more recently infants and pregnant
women have been included in early phase studies [2]. On
the contrary, candidate vaccines have not been tested in
adolescents. Currently, phase I/II vaccine trials are being
carried out with the adult population in Soweto. The
United States Food and Drug Administration (FDA), one
of the regulatory bodies involved in oversight of clinical
trials of HIV vaccines, stipulates that a drug cannot be
licensed for use in a population in which it has not been
tested. For this reason, lack of adolescent participation in
HIV vaccine trials will only delay access of this age group
to a vaccine once it is available [9]. Willingness of adoles-
cents to enrol in HIV vaccine clinical trials is therefore an
important factor in planning such initiatives.
Prior studies indicate that willingness to participate in
future HIV vaccine trials is contingent on vaccine knowl-
edge and to hypothetical trial attributes [10,11]. Men who
have sex with men (MSM), whose baseline knowledge of
HIV vaccines was very low, became unwilling to partici-
pate with increased knowledge. However, other findings
have not borne out such a relationship, with one study
suggesting that high levels of knowledge regarding HIV
vaccines may lead to the increased likelihood of participa-
tion [12], while another did not find a relationship
between knowledge and willingness to participate [13].
Willingness to participate in a hypothetical vaccine clini-
cal trial may not reflect willingness to participate in an
actual trial [10,14]. Some of the factors, identified among
adults, that would discourage participation in HIV vaccine
clinical trials include mistrust of medical research, social
harms, and concerns regarding vaccine safety and vaccine-
induced HIV seropositivity [10,11,13]. Some of the per-
ceived benefits of trial participation include risk reduction
counselling, altruism, and possible protection from the
vaccine.
Other challenges inherent in adolescent clinical trial par-
ticipation include many socio-legal and psychological
considerations. In particular, adolescents may lack cogni-
tive maturity to weigh the pros and cons of clinical trial
participation [15]. This is further complicated by the
importance of peer pressure on decision making. Adoles-
cent participation in clinical trials requires parental con-
sent, potentially compromising the privacy and
confidentiality of the participant. Another important con-
sideration when planning adolescent participation in
clinical trials is to build in flexibility that will accommo-
date the needs of the adolescents.
To begin to understand adolescent attitudes to these com-
plex issues, and inform our future work with adolescents
in HIV vaccine trials, we undertook a formative study
examining attitudes towards such trials, potential moti-
vating factors and hypothetical willingness to participate,
among Soweto youth. There are varied meanings of 'ado-
lescent'; in this research we used the psychological sense
of the intermediate time of development between child-
hood and maturity, rather than in a legal sense referring to
a specific age, although examined responses in relation to
the specific age, given age would be an eligibility criterion
in trials.
Methods
We undertook a study of attitudes to HIV vaccine trial par-
ticipation among high school students in Soweto from
August 2005 to February 2006. This study was approved
by the University of the Witwatersrand Human Research
Ethics Committee (protocol number MO50101).
Approval was also provided by each school head teacher
and the Gauteng Department of Education. Consultations
were held with school governing bodies prior to initiation
of the survey within each school.
Participants
A two-stage sampling procedure was used. The first stage
sampling units were all 72 public high schools in Soweto.
Ten schools were randomly selected. Based on our esti-
mates of class numbers and response rates, we planned to
enrol students at four schools; we oversampled from the
first stage pool to provide for potential non-agreement to
conduct the research at a selected school. The first four
randomly chosen schools were approached regarding par-
ticipation and all agreed. All pupils within the selected
schools from whom parental consent and child assent
could be obtained were eligible for participation.
Measures
A self-administered, facilitated questionnaire was admin-
istered to all participants [see Additional File 1]. The ques-
tionnaire explored general HIV knowledge, perception of
adolescent risk, knowledge of vaccine concepts, willing-BMC Research Notes 2008, 1:76 http://www.biomedcentral.com/1756-0500/1/76
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ness to participate in future vaccine trials, perceived per-
sonal and social harms and benefits associated with
participation as well as barriers and facilitators to partici-
pating in future HIV vaccine trials.
The measures administered were based and adapted from
a similar survey conducted among high-risk populations
in the United States [10]. The items were adapted for com-
prehensibility and local idiomatic language use, and
piloted prior to use in the school setting. The items had
not been validated in prior work in South Africa, to our
knowledge.
Sample size
The sample size was estimated based on an initial assump-
tion that 20% of adolescents would be willing to enrol in
an HIV vaccine trial. To compare the hypothesized value
against an alternative proportion of 50%, with type 1 error
rate of 0.05 and 90% power, we estimated that 23
respondents would be required within each stratum. We
will therefore recruit a minimum of 25 children of each
gender within each of three age strata: < 13 years, 13 – 14
years, and 15 – 18 years. The minimum sample size for the
questionnaire portion of this study will therefore be 150
participants.
Results
277 school-going youth (mean age 16.2 years; range 10 –
25; 53.1% female) provided assent or consent to partici-
pate, and if under 18, we also obtained written consent
from a parent. The response rate to the survey is not
known. Not all data fields were adequately responded to,
resulting in missing data for some items.
Perceptions And Attitudes To Adolescent Sexuality And 
HIV Testing
Of the 241 participants who responded to the question on
HIV testing, 10% indicated that they have tested for HIV
(Table 1). Of those who responded that they had not pre-
viously tested, almost half (46%) of the participants
stated that a reason for not testing was that they believed
that they were not at risk of HIV infection, while 44%
stated the reason was that they were afraid to test for HIV.
More than half of the participants believed that sexual
debut in Soweto is as early as 9 years of age and 43%
believed that 9 year olds were vulnerable to HIV infection.
However, less than half of the participants believed that
adults talk to children that age about HIV. The majority
(57%) of participants believed that parents should give
permission for their child's HIV test while most of the par-
ticipants (84%) believed that parents should know the
HIV status of their child.
Trial Participation And Stigma
HIV stigma did not appear to impact on willingness to
participate in a future trial. Most respondents felt that
potential discrimination, being avoided as a result of trial
participation, being perceived as at high risk of HIV, or
being thought to have AIDS would not influence their
decision to participate in trials (Table 2).
Willingness To Participate In Future HIV Vaccine Trials 
And Associated Factors
Of the 240 responses to the willingness item, 84 (35%)
indicated they were "probably willing" and 126 (52.5%)
that they were "definitely willing" to join a study of a vac-
cine to prevent HIV. Combined, willingness to participate
('definitely' and 'probably') was 88.2% (95% confidence
interval 84.1% – 92.3%, p < 0.00001). There were no sig-
nificant differences in willingness by gender, age, school
grade, or institution. Factors that were rated as "very
important" in determining willingness included receiving
current information about HIV research [n = 201 (89%)],
that they would be doing something to honour people
who have HIV or AIDS or have died of AIDS [n = 168
(71%)], getting free counselling and testing every six
months [n = 168 (71%)], that participants may receive
some protection against HIV infection from the vaccine [n
= 160 (71%)], and would feel more motivated to avoid
risky behaviour [n = 134 (59%)] (Table 3).
Discussion
Sexual debut in Soweto was perceived to be very early,
exposing adolescents to HIV. Ten percent of the partici-
pants in this study reported having previously testing for
HIV. This figure perhaps reflects the difficulties in access-
ing HIV testing for Soweto youth. Comparative figures for
testing uptake in Soweto are not available; however,
national surveys report rates of prior testing of 30.5%
among people 15 years and older [16]. Similar to other
reports emanating from South Africa (6), youth in this
believed that they were at risk of HIV acquisition. How-
ever, the proportion of participants who thought that they
were not at risk is still high in light of the prevalence of
HIV in young adults and the belief expressed that sexual
Table 1: Questions Exploring Perceptions And Attitudes To 
Adolescent Sexuality And HIV Testing
n (%)
I have tested for HIV 24 (10)
I do not think I am risk of HIV infection 110 (46)
I am afraid to get tested for HIV 107 (44)
My parents should know my HIV test results 198 (84)
Children age 9 are beginning to be sexually active 133 (56)
Adults talk to children between 9–10 about HIV 111 (47)
HIV is a threat to children from age 9 102 (43)
My parents should give permission for my HIV test 135 (57)
*Values may not add up to total number of participants as some fields 
had missing data.BMC Research Notes 2008, 1:76 http://www.biomedcentral.com/1756-0500/1/76
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debut is early. The high proportion of participants who
believed that parents should give permission for the HIV
testing and know the HIV status of their child indicates
interdependence between parents and their children
although this is not without problems. Parental involve-
ment in adolescent trial participation will have to be
thought out very carefully to balance the need for privacy
and autonomous decision-making and the need to have
adults oversee adolescent participation in vaccine clinical
trials.
Soweto school-going youth report high degrees of willing-
ness to participate in future HIV vaccine trials. Participants
indicated that access to regular counselling and testing,
current information, and potential impact on motivation
to reduce risk behaviour were very important for deter-
mining willingness to participate. Whether hypothetical
willingness translates to participation will await data from
adolescent HIV vaccine trials. In the same vein, consider-
ation given to factors that may encourage or discourage
participation in such trials may differ from a hypothetical
to an actual trial. However, that being said, the enormous-
ness of the HIV and AIDS epidemic in South Africa has
fostered a culture of participation in HIV/AIDS-related ini-
tiatives. In this regard, HIV stigma may be a minor consid-
eration in such decisions. Some recent data suggest that
HIV stigma may no longer be a major influence in deci-
sions relating to HIV and AIDS [16]. Further, several inter-
national studies point out that willingness to participate
in a hypothetical HIV vaccine study is strongly associated
with being at high risk for HIV infection [10,17,18].
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Table 2: Questions Exploring Stigma Resulting From HIV Vaccine Trial Participation
How important is stigma in making decisions about trial participation? Very n (%) Somewhat n (%) Slightly n (%) Not at all n (%)
I may be discriminated against at school if I volunteer 41 (18) 30 (13) 32 (14) 130 (56)
People may avoid me if I volunteer in a vaccine trial 40 (17) 25 (11) 41 (17) 132 (55)
People may think I have HIV or AIDS if I volunteer in a vaccine trial 26 (11) 37 (17) 37 (17) 136 (58)
People may think I am at high risk of HIV if I am in a study 44 (19) 32 (14) 38 (16) 117 (51)
People may not want to have sex with me if I am in a study 56 (23) 17 (7) 35 (15) 132 (55)
Table 3: Factors Influencing Willingness To Participate In HIV Vaccine Trials
n (%) indicating factor was "very important" in relation to willingness
I would get free counseling and HIV testing at least once every 6 months 167/237 (70.5)
I would get current information about HIV research 201/226 (88.9)
I may feel more motivated to avoid risky behavior 134/224 (59.8)
I would get a small amount of money each time I came for a visit 58/238 (24.4)
I may get some protection against HIV infection from the vaccine 160/228 (70.2)
I would be doing something to honor people who have HIV or have died of 
AIDS
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